NCT01994382 2022-04-05Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLAlexion Pharmaceuticals, Inc.Phase 1/2 Completed260 enrolled 33 charts
NCT01116232 2019-03-26Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell TransplantationBarbara Ann Karmanos Cancer InstitutePhase 2 Terminated4 enrolled 4 charts